HUTCHMED (China) Limited

Healthcare · Drug Manufacturers - Specialty & Generic · Hong Kong

Last price 13.15 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.31B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...